Explore the different strengths of brigatinib/brigatinib

Brigatinib/Brigatinib, also known as Alunbrig, is an important targeted therapy drug mainly used to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). This drug has received widespread attention for its high efficacy and relatively few side effects.

The specifications of brigatinib are mainly reflected in its dosage and dosage form. The drug usually exists in the form of tablets, with various dosage strengths, such as 30 mg, 90 mg and 180 mg. Tablets of different doses can meet the needs of patients with different conditions and constitutions, making treatment more personalized and precise.

The specifications of brigatinib are also reflected on its packaging. The packaging specifications of brigatinib produced by different manufacturers may be different. For example, some manufacturers produce brigatinib in a box of 7 tablets, 90 mg each; some manufacturers produce 28 tablets in a box, 30 mg or 90 mg each; and some manufacturers produce brigatinib in a box of 30 tablets, 90 mg each. These different packaging specifications make it easier for patients and doctors to choose according to their treatment needs.

The specifications of brigatinib also reflect its production process and quality control level. As an efficient and safe targeted therapy drug, the production process of brigatinib needs to strictly follow Good Manufacturing Practices (GMP) to ensure that every tablet of the drug meets quality standards. This includes requirements for the purity of raw materials, tablet stability, solubility, etc.

It is worth mentioning that the specifications of brigatinib are also closely related to its indications and dosage. The drug is mainly used to treat ALK-positive non-small cell lung cancer and is usually administered orally. This method of medication is convenient for patients to take it at home, while also reducing the inconvenience and risks that may be caused by injections and other drug administration methods.